Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cellectis S.A (ALCLS) Fair Value & Analysis

Healthcare · FR · Market cap €309M

Price€2.51
Fair Value€4.70
Upside+87.4%
Quality95/100
Evidence: Low Range €3.53 – €5.88

Fair value as of: Jun 24, 2026

Analysis

Cellectis S.A (ALCLS) currently trades at €2.51, while our model-based Fair Value estimate is €4.70 — implying the stock looks roughly 87.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Cellectis S.A (ALCLS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €4.70 versus a price of €2.51 — about +87% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ALCLS?
Our 21-model fair value for Cellectis S.A is €4.70 (as of Jun 24, 2026), built from audited fundamentals. The current price is €2.51.
What is the quality score of ALCLS?
Cellectis S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.